8-K: OrthoPediatrics Corp. Announces Record Preliminary Unaudited Revenue for 2024 and Issues Positive 2025 Guidance

OrthoPediatrics Corp. reports record preliminary unaudited revenue for full year 2024 and provides financial guidance for 2025, projecting continued growth and profitability.

Summary

• OrthoPediatrics Corp. announced preliminary unaudited financial highlights for Q4 and full year 2024, along with 2025 financial guidance.
• The company achieved record full year 2024 revenue of $204.7 million, a 38% increase compared to $148.7 million in 2023.
• Domestic net revenue for 2024 is expected to be $161.1 million, representing 45% annual growth, while international net revenue is expected to be $43.6 million, representing 16% annual growth.
• For Q4 2024, net revenue is expected to be $52.7 million, a 40% increase compared to $37.6 million in Q4 2023.
• Domestic net revenue for Q4 is expected to be $42.9 million (52% growth), and international net revenue is expected to be $9.8 million (5% growth).
• OrthoPediatrics projects 2025 revenue to be in the range of $235 million to $242 million, representing 15% to 18% growth compared to 2024.
• The company expects annual set deployment to be approximately $15 million and adjusted EBITDA to be between $15 million to $17 million for 2025.
• The company plans to release its fourth quarter and full year 2024 financial results and provide additional commentary on its financial outlook in early March.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with record revenue, strong growth, and optimistic future guidance, indicating a very positive sentiment.

Positives

• The company achieved record revenue for full year 2024.
• The company experienced significant growth in both domestic and international markets.
• The company is projecting continued revenue growth and positive adjusted EBITDA for 2025.
• The company's specialty bracing business (OPSB) is performing well and is seen as a significant market opportunity.
• The company has helped over 1.1 million children since inception.

Risks

• The preliminary financial results are unaudited and subject to adjustment.
• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• The company's future results and net revenue could differ materially from the forecasted amounts.

Future Outlook

OrthoPediatrics projects continued revenue growth in 2025, with revenue expected to be in the range of $235 million to $242 million, and adjusted EBITDA between $15 million and $17 million.

Management Comments

• Throughout 2024 we continued to deliver strong results, advance our strategic initiatives, and grow our market share within pediatric orthopedics.
• Our Trauma and Deformity and Scoliosis businesses continue to execute and contribute to our overall growth as we drove topline revenue and significantly increased profitability.
• We are extremely pleased with the specialty bracing (OPSB) business performance.
• It has proven to be a tremendous market opportunity and provided an important strategic catalyst to further support our current customers.
• As we look ahead, we are confident we have the right growth drivers in place to execute against our long-term outlook and deliver results all while we continue to make an impact for children.

Industry Context

The announcement reflects a positive outlook for OrthoPediatrics within the pediatric orthopedics market, indicating successful execution of strategic initiatives and growth in market share. The company's focus on specialty bracing also suggests a strategic move to capitalize on emerging opportunities within the broader orthopedic market.

Comparison to Industry Standards

• Without specific competitor data in this document, a direct comparison is challenging.
• However, a 38% revenue growth rate in the orthopedic device industry is generally considered strong, suggesting OrthoPediatrics is performing well relative to its peers.
• Companies like Stryker, Johnson & Johnson (DePuy Synthes), and Zimmer Biomet are much larger but serve the broader orthopedics market, making a direct comparison less relevant.
• A more relevant comparison would be to smaller, specialized orthopedic companies focused on pediatric or niche markets, but this requires additional research.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and positive financial guidance.
• Employees may be motivated by the company's success and future growth prospects.
• Customers (healthcare providers) may benefit from the company's continued innovation and product offerings.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower-risk borrower due to its strong financial performance.

Next Steps

• The company plans to release its fourth quarter and full year 2024 financial results and provide additional commentary on its financial outlook in early March.

Key Dates